XPO1 and cervical carcinoma: In support of this, leptomycin B (LMB), a Crm1 inhibitor, has been shown to reduce E6's ability to degrade p53 in cervical carcinoma cells [39], [42] and cause: (i) retention of STAT1-NES construct in the nucleus [34], [35], (ii) nuclear accumulation and activation of p53, (iii) induction of specific downstream target genes of p53 [42]–[45] and (iv) growth arrest and a senescent-like phenotype primary prostate epithelial cells and fibroblasts.